Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00919581 · ClinicalTrials.gov registry record
Pilot Study: The Role of Macrophage Migration Inhibitory Factor (MIF) in Spinal Cord Injury
A clinical trial, sponsored by Northwell Health.
- Completed
- Registry status
- 149
- Enrollment target
NCT00919581 is a clinical trial that has completed, run by Northwell Health. The registered enrollment target is 149 participants.
The verdict
NCT00919581 has completed, sponsored by Northwell Health.
- COMPLETED
- Registry status
- 149 participants
- Enrollment target
Study Summary
The purpose of the study is to investigate inflammatory and other substances that may be elevated in the blood and blood cells following spinal cord injury (SCI). These substances will be evaluated in samples from people who have had a spinal cord injury due to trauma (e.g. car accident or a fall) within the first week (acute) or at least one year ago (chronic). Specifically, the study will evaluate the presence and levels of a protein, macrophage migration inhibitory factor (MIF). MIF is released by cells and has a specific effect on the way cells behave, communicate and work together. In several other medical conditions, MIF is known to increase inflammation in the body. By comparing blood samples from individuals with spinal cord injury and uninjured (no spinal cord injury) individuals, the investigators will try to find out if MIF levels are increased in people with SCI. Investigators will also use these samples to measure other proteins that increase inflammation in the body and to see if the biological activities of MIF can be reduced in a test tube by adding other substances to the blood samples. It is hoped that this study of MIF and other proteins related to inflammation will help improve the treatment of SCI in the future. We hope to enroll a total of 312 subjects in this study (50 with acute spinal cord injury, 125 with chronic spinal cord injury, and 137 uninjured individuals).
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 149 participants |
| Start Date | 2009-05 |
| Est. Completion | 2016-12 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00919581
The ClinicalTrials.gov registry entry for NCT00919581 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 149 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwell Health, which has 370 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT00919581 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00919581 about?
NCT00919581 is a clinical study titled "Pilot Study: The Role of Macrophage Migration Inhibitory Factor (MIF) in Spinal Cord Injury". The purpose of the study is to investigate inflammatory and other substances that may be elevated in the blood and blood cells following spinal cord injury (SCI). These substances will be evaluated in samples from people who have had a spinal cord injury due to trauma (e.g. car accident or a fall) w...
What is the current status of trial NCT00919581?
This trial is currently completed. The enrollment target is 149 participants. The study started on 2009-05. Estimated completion is 2016-12.
Who is sponsoring clinical trial NCT00919581?
This trial is sponsored by Northwell Health, which has 370 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.